Biopharma support service launched

Two leading UK biopharmaceutical business development companies, Bridgehead Technologies and Pharmalicensing, are to merge.

Bridgehead Technologies is a leading specialist international consultancy providing due diligence, valuation and strategy advice to the life sciences and medical technologies sectors, while Pharmalicensing is the leading global online partner for biopharmaceutical business development. The merger will result in the formation of The Bridgehead Pharmalicensing Group, a full service business aimed at supplying the needs of companies world wide, ranging from small biotechnology start-ups to leading pharmaceutical and medical companies.

The two companies will continue to trade under their own names, but in addition a powerful new product licensing and technology transfer service for medical and life sciences companies will be launched, backed by their joint expertise.

Dr Fiona Paton, chairman of the new company, said: 'The merger represents a strategic move in a business-critical discipline. We have identified product sourcing in the pharmaceutical, medical and life sciences industries as a major growth area.'

'The new company will be uniquely positioned not only to bring dealmakers together but also to improve the efficiency of the whole licensing and acquisition process for client companies,' added Steve Poile, founder and managing director of Pharmalicensing.

Although its international headquarters will be in the UK, the group will have offices and associates in all major countries. It will offer both strategic and implementation services through all phases of product development and commercial lifecycles.